PURE Bioscience Reports Fiscal Second Quarter 2025 Financial Results
PURE Bioscience (OTCQB: PURE) reported its fiscal Q2 2025 financial results, showing mixed performance. Net product sales increased to $391,000 in Q2 2025 from $325,000 in Q2 2024, driven by expanded distribution network sales. The company reduced its quarterly net loss to $798,000 from $1,002,000 year-over-year.
For the six-month period, net product sales decreased to $946,000 from $1,043,000, while net loss improved to $1,487,000 from $1,737,000. The company achieved significant cost reductions through decreased personnel costs, professional fees, and share-based compensation.
A major milestone was advancing their dairy membrane solutions from laboratory testing to pilot scale at a California State University and commercial in-plant pilots. The company's non-oxidizing membrane solution for dairy operations demonstrates benefits in water conservation, energy efficiency, fouling removal, and operational cost reduction through minimized Clean-In-Place cycle downtime.
PURE Bioscience (OTCQB: PURE) ha riportato i risultati finanziari per il secondo trimestre fiscale del 2025, mostrando una performance mista. Le vendite nette di prodotti sono aumentate a 391.000 dollari nel secondo trimestre del 2025 rispetto a 325.000 dollari nel secondo trimestre del 2024, grazie all'espansione della rete di distribuzione. L'azienda ha ridotto la sua perdita netta trimestrale a 798.000 dollari rispetto a 1.002.000 dollari dell'anno precedente.
Per il periodo di sei mesi, le vendite nette di prodotti sono diminuite a 946.000 dollari rispetto a 1.043.000 dollari, mentre la perdita netta è migliorata a 1.487.000 dollari rispetto a 1.737.000 dollari. L'azienda ha ottenuto significative riduzioni dei costi attraverso la diminuzione dei costi del personale, delle spese professionali e della compensazione basata sulle azioni.
Un traguardo importante è stato il passaggio delle loro soluzioni a membrana per latticini da test di laboratorio a scala pilota presso una università statale della California e piloti commerciali in impianto. La soluzione a membrana non ossidante dell'azienda per le operazioni lattiero-casearie dimostra vantaggi nella conservazione dell'acqua, nell'efficienza energetica, nella rimozione delle incrostazioni e nella riduzione dei costi operativi grazie alla minimizzazione dei tempi di inattività del ciclo Clean-In-Place.
PURE Bioscience (OTCQB: PURE) informó sobre sus resultados financieros del segundo trimestre fiscal de 2025, mostrando un desempeño mixto. Las ventas netas de productos aumentaron a 391,000 dólares en el segundo trimestre de 2025 desde 325,000 dólares en el segundo trimestre de 2024, impulsadas por las ventas de una red de distribución ampliada. La compañía redujo su pérdida neta trimestral a 798,000 dólares desde 1,002,000 dólares en comparación con el año anterior.
Durante el período de seis meses, las ventas netas de productos disminuyeron a 946,000 dólares desde 1,043,000 dólares, mientras que la pérdida neta mejoró a 1,487,000 dólares desde 1,737,000 dólares. La compañía logró reducciones significativas de costos a través de la disminución de los costos de personal, honorarios profesionales y compensación basada en acciones.
Un hito importante fue avanzar sus soluciones de membrana para lácteos de las pruebas de laboratorio a la escala piloto en una universidad estatal de California y pilotos comerciales en planta. La solución de membrana no oxidante de la compañía para operaciones lácteas demuestra beneficios en la conservación del agua, la eficiencia energética, la eliminación de incrustaciones y la reducción de costos operativos mediante la minimización del tiempo de inactividad del ciclo Clean-In-Place.
PURE Bioscience (OTCQB: PURE)는 2025 회계 연도 2분기 재무 결과를 발표하며 혼합된 실적을 보였습니다. 제품의 순 매출은 2024년 2분기 325,000달러에서 2025년 2분기 391,000달러로 증가했으며, 이는 확장된 유통 네트워크 판매에 의해 촉진되었습니다. 회사는 분기 순손실을 작년 1,002,000달러에서 798,000달러로 줄였습니다.
6개월 동안의 기간 동안 제품의 순 매출은 1,043,000달러에서 946,000달러로 감소했으며, 순손실은 1,737,000달러에서 1,487,000달러로 개선되었습니다. 회사는 인건비, 전문 수수료 및 주식 기반 보상의 감소를 통해 상당한 비용 절감을 달성했습니다.
중요한 이정표는 유제품 멤브레인 솔루션을 캘리포니아 주립대학에서 파일럿 규모로 실험실 테스트에서 상업적 인플랜 파일럿으로 발전시킨 것입니다. 회사의 비산화성 멤브레인 솔루션은 수자원 보존, 에너지 효율성, 오염물 제거 및 Clean-In-Place 사이클 다운타임 최소화를 통한 운영 비용 절감의 이점을 보여줍니다.
PURE Bioscience (OTCQB: PURE) a annoncé ses résultats financiers pour le deuxième trimestre de l'exercice 2025, montrant une performance mitigée. Les ventes nettes de produits ont augmenté à 391 000 dollars au deuxième trimestre de 2025 contre 325 000 dollars au deuxième trimestre de 2024, soutenues par des ventes d'un réseau de distribution élargi. L'entreprise a réduit sa perte nette trimestrielle à 798 000 dollars contre 1 002 000 dollars d'une année sur l'autre.
Pour la période de six mois, les ventes nettes de produits ont diminué à 946 000 dollars contre 1 043 000 dollars, tandis que la perte nette s'est améliorée à 1 487 000 dollars contre 1 737 000 dollars. L'entreprise a réalisé des réductions de coûts significatives grâce à la diminution des coûts de personnel, des honoraires professionnels et de la rémunération en actions.
Un jalon majeur a été l'avancement de leurs solutions de membrane laitière des tests en laboratoire à l'échelle pilote dans une université d'État de Californie et des pilotes commerciaux en usine. La solution de membrane non oxydante de l'entreprise pour les opérations laitières présente des avantages en matière de conservation de l'eau, d'efficacité énergétique, d'élimination des encrassements et de réduction des coûts opérationnels grâce à la minimisation des temps d'arrêt du cycle Clean-In-Place.
PURE Bioscience (OTCQB: PURE) hat seine finanziellen Ergebnisse für das zweite Quartal des Geschäftsjahres 2025 veröffentlicht, die eine gemischte Leistung zeigen. Der Nettoumsatz von Produkten stieg im zweiten Quartal 2025 auf 391.000 Dollar von 325.000 Dollar im zweiten Quartal 2024, was auf den Verkauf über ein erweitertes Vertriebsnetz zurückzuführen ist. Das Unternehmen verringerte seinen vierteljährlichen Nettoverlust auf 798.000 Dollar von 1.002.000 Dollar im Jahresvergleich.
Im Zeitraum von sechs Monaten sank der Nettoumsatz von Produkten auf 946.000 Dollar von 1.043.000 Dollar, während sich der Nettoverlust auf 1.487.000 Dollar von 1.737.000 Dollar verbesserte. Das Unternehmen erzielte erhebliche Kostensenkungen durch reduzierte Personalkosten, professionelle Gebühren und aktienbasierte Vergütung.
Ein wichtiger Meilenstein war der Übergang ihrer Membranlösungen für Milchprodukte von Labortests zur Pilotgröße an einer staatlichen Universität in Kalifornien und zu kommerziellen In-Plant-Piloten. Die nicht oxidierende Membranlösung des Unternehmens für Milchbetriebe zeigt Vorteile in der Wassereinsparung, Energieeffizienz, Fouling-Entfernung und Betriebskostenreduzierung durch minimierte Ausfallzeiten des Clean-In-Place-Zyklus.
- Q2 2025 revenue increased 20.3% year-over-year to $391,000
- Q2 net loss reduced by 20.4% to $798,000 from $1,002,000
- Successful advancement of dairy membrane solutions to commercial pilot phase
- Significant reduction in operating expenses through cost-cutting measures
- Six-month revenue declined 9.3% to $946,000 from $1,043,000
- Company continues to operate at a loss ($798,000 in Q2)
- Decreased sales across end-user network in six-month period
Summary of Results – Fiscal Second Quarter Operations
-
Net product sales were
and$391,000 for the fiscal second quarter ended January 31, 2025 and 2024, respectively. The increase of$325,000 was attributable to increased sales across our distribution network.$66,000 -
Net loss for the fiscal second quarter ended January 31, 2025, was
, compared to$798,000 for the fiscal second quarter ended January 31, 2024. Selling, general, and administrative expenses decreased by$1,002,000 . The decrease was due to reductions in personnel costs, professional service fees, and share-based compensation.$194,000 -
Net loss, excluding share-based compensation, for the fiscal second quarter ended January 31, 2025, was
, compared to$771,000 for the fiscal second quarter ended January 31, 2024.$938,000 -
Net loss per share was (
) for the fiscal second quarters ended January 31, 2025 and 2024, respectively.$0.01
Summary of Results – Prior Six Months
-
Net product sales were
and$946,000 for the six months ended January 31, 2025 and 2024, respectively. The decrease of$1,043,000 was attributable to decreased sales across our end-user network.$97,000 -
Net loss for the six months ended January 31, 2025, was
, compared to$1,487,000 for the six months ended January 31, 2024. Selling, general and administrative expenses decreased by$1,737,000 . The decrease was due to reductions in personnel costs, professional service fees, and share-based compensation.$386,000 -
Net loss, excluding share-based compensation, for the six months ended January 31, 2025, was
, compared to$1,403,000 for the six months ended January 31, 2024.$1,593,000 -
Net loss per share was (
) for the six months ended January 31, 2025, compared to$0.01 for the six months ended January 31, 2024.$(0.02)
Robert Bartlett, Chief Executive Officer, stated, “Our fiscal second quarter year-over-year sales growth demonstrates the progress we are making with our direct customers and distribution network. This quarter’s biggest accomplishment was advancing our dairy membrane solutions from the microbiological laboratory bench work to the Dairy Pilot Processing Center for scale-up testing at a leading California State University and into full-scale commercial in-plant pilots. Since the launch of our in-plant pilot program, we have been working closely with our distribution partners for success in the field.”
Successful pilot treatments of both Ultra-Filtration (UF) and Reverse Osmosis (RO) membrane systems have been pivotal in proving the viability of the Company’s solution in the dairy industry. These treatments have provided invaluable data necessary to move forward with launching a new solution that promises to revolutionize the industry.
The new non-oxidizing membrane solution offers a range of benefits, including conserving water and energy, removing fouling, restoring throughput, and prolonging membrane life. Furthermore, it reduces operational costs by minimizing Clean-In-Place cycle downtime, a critical factor in dairy operations.
“We are committed to expanding the availability of this innovative solution and improving operational efficiency in the dairy industry,” concluded Bartlett.
About PURE Bioscience, Inc.
PURE is committed to redefining chemical safety through its innovative technology. With a focus on efficacy and effectiveness, PURE develops advanced solutions that meet the highest safety standards and produce best-in-class results for its consumers and distributors. PURE continues to focus on developing and commercializing our proprietary antimicrobial products, primarily in the food and beverage industry. We provide solutions to combat the health and environmental challenges of pathogens and hygienic control. Our technology platform is based on patented, stabilized ionic silver, and our initial products contain silver dihydrogen citrate, better known as SDC. This broad-spectrum, non-toxic antimicrobial agent formulates well with other compounds. As a platform technology, SDC is distinguished from existing products in the marketplace because of its superior efficacy, reduced toxicity, and mitigation of bacterial resistance. Additional information on PURE is available at www.purebio.com.
Forward-looking Statements: Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. Statements in this press release, including quotes from management, concerning the Company’s expectations, plans, business outlook, future performance, future potential revenues, expected results of the Company’s marketing efforts, the execution of contracts under negotiation, and any other statements concerning assumptions made or expectations as to any future events, conditions, performance or other matters, are “forward-looking statements.” Forward-looking statements inherently involve risks and uncertainties that could cause our actual results to differ materially from any forward-looking statements. Factors that could cause or contribute to such differences include, but are not limited to, the Company’s failure to implement or otherwise achieve the benefits of its proposed business initiatives and plans; acceptance of the Company’s current and future products and services in the marketplace, including the Company’s ability to convert successful evaluations and tests for PURE Control and PURE Hard Surface into customer orders and customers continuing to place product orders as expected and to expand their use of the Company’s products; the Company’s ability to maintain relationships with its partners and other counterparties; the Company’s ability to generate sufficient revenues and reduce its operating expenses in order to reach profitability; the Company’s ability to raise the funding required to support its continued operations and the implementation of its business plan; the ability of the Company to develop effective new products and receive required regulatory approvals for such products, including the required data and regulatory approvals required to use its SDC-based technology as a direct food contact processing aid in raw meat processing; competitive factors, including customer acceptance of the Company’s SDC-based products that are typically more expensive than existing treatment chemicals; dependence upon third-party vendors, including to manufacture its products; and other risks detailed in the Company’s periodic report filings with the Securities and Exchange Commission (the SEC), including its Form 10-K for the fiscal year ended July 31, 2024, Form 10-Q for the fiscal first quarter ended October 31, 2024, and Form 10-Q for the fiscal second quarter ended January 31, 2025. You should not place undue reliance on these forward-looking statements, which speak only as of the date of this press release. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release.
PURE Bioscience, Inc. Condensed Consolidated Balance Sheets |
||||||||
|
|
January 31, 2025 |
|
July 31, 2024 |
||||
|
|
(Unaudited) |
|
|
||||
Assets |
|
|
|
|
|
|
||
Current assets |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
202,000 |
|
|
$ |
349,000 |
|
Accounts receivable |
|
|
180,000 |
|
|
|
298,000 |
|
Inventories, net |
|
|
75,000 |
|
|
|
56,000 |
|
Restricted cash |
|
|
75,000 |
|
|
|
75,000 |
|
Prepaid expenses |
|
|
30,000 |
|
|
|
27,000 |
|
Total current assets |
|
|
562,000 |
|
|
|
805,000 |
|
Property, plant and equipment, net |
|
|
12,000 |
|
|
|
13,000 |
|
Total assets |
|
$ |
574,000 |
|
|
$ |
818,000 |
|
Liabilities and stockholders’ deficiency |
|
|
|
|
|
|
||
Current liabilities |
|
|
|
|
|
|
||
Accounts payable |
|
$ |
700,000 |
|
|
$ |
601,000 |
|
Accrued liabilities |
|
|
166,000 |
|
|
|
132,000 |
|
Total current liabilities |
|
|
866,000 |
|
|
|
733,000 |
|
Long-term liabilities |
|
|
|
|
|
|
||
Convertible notes payable to related parties |
|
|
3,975,000 |
|
|
|
2,949,000 |
|
Total long-term liabilities |
|
|
3,975,000 |
|
|
|
2,949,000 |
|
Total liabilities |
|
|
4,841,000 |
|
|
|
3,682,000 |
|
Commitments and contingencies |
|
|
|
|
|
|
||
Stockholders’ deficiency |
|
|
|
|
|
|
||
Preferred stock, |
|
|
— |
|
|
|
— |
|
Common stock, |
|
|
1,119,000 |
|
|
|
1,119,000 |
|
Additional paid-in capital |
|
|
132,696,000 |
|
|
|
132,612,000 |
|
Accumulated deficit |
|
|
(138,082,000 |
) |
|
|
(136,595,000 |
) |
Total stockholders’ deficiency |
|
|
(4,267,000 |
) |
|
|
(2,864,000 |
) |
Total liabilities and stockholders’ deficiency |
|
$ |
574,000 |
|
|
$ |
818,000 |
|
PURE Bioscience, Inc. Condensed Consolidated Statements of Operations (Unaudited) |
||||||||||||||||
|
|
Six Months Ended |
|
Three months Ended |
||||||||||||
|
|
January 31, |
|
January 31, |
||||||||||||
|
|
2025 |
|
|
2024 |
|
|
2025 |
|
|
2024 |
|
||||
Net product sales |
|
$ |
946,000 |
|
|
$ |
1,043,000 |
|
|
$ |
391,000 |
|
|
$ |
325,000 |
|
Royalty revenue |
|
|
1,000 |
|
|
|
5,000 |
|
|
|
— |
|
|
|
1,000 |
|
Total revenue |
|
|
947,000 |
|
|
|
1,048,000 |
|
|
|
391,000 |
|
|
|
326,000 |
|
Cost of goods sold |
|
|
395,000 |
|
|
|
429,000 |
|
|
|
164,000 |
|
|
|
149,000 |
|
Gross profit |
|
|
552,000 |
|
|
|
619,000 |
|
|
|
227,000 |
|
|
|
177,000 |
|
Operating costs and expenses |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Selling, general and administrative |
|
|
1,752,000 |
|
|
|
2,138,000 |
|
|
|
871,000 |
|
|
|
1,065,000 |
|
Research and development |
|
|
152,000 |
|
|
|
156,000 |
|
|
|
81,000 |
|
|
|
76,000 |
|
Total operating costs and expenses |
|
|
1,904,000 |
|
|
|
2,294,000 |
|
|
|
952,000 |
|
|
|
1,141,000 |
|
Loss from operations |
|
|
(1,352,000 |
) |
|
|
(1,675,000 |
) |
|
|
(725,000 |
) |
|
|
(964,000 |
) |
Other income (expense) |
|
|
|
|
|
|
|
|
|
|
|
|
||||
Other income (expense), net |
|
|
(3,000 |
) |
|
|
— |
|
|
|
(3,000 |
) |
|
|
— |
|
Interest expense, net |
|
|
(132,000 |
) |
|
|
(62,000 |
) |
|
|
(70,000 |
) |
|
|
(38,000 |
) |
Total other income (expense) |
|
|
(135,000 |
) |
|
|
(62,000 |
) |
|
|
(73,000 |
) |
|
|
(38,000 |
) |
Net loss |
|
$ |
(1,487,000 |
) |
|
$ |
(1,737,000 |
) |
|
$ |
(798,000 |
) |
|
$ |
(1,002,000 |
) |
Basic and diluted net loss per share |
|
$ |
(0.01 |
) |
|
$ |
(0.02 |
) |
|
$ |
(0.01 |
) |
|
$ |
(0.01 |
) |
Shares used in computing basic and diluted net loss per share |
|
|
111,856,473 |
|
|
|
111,856,473 |
|
|
|
111,856,473 |
|
|
|
111,856,473 |
|
PURE Bioscience, Inc. Condensed Consolidated Statement of Stockholders’ Equity (Deficiency) (Unaudited) |
||||||||||||||||||||||||||||||||||||||||
|
|
Six Months Ended January 31, 2025 |
|
Six Months Ended January 31, 2024 |
||||||||||||||||||||||||||||||||||||
|
|
Common Stock |
|
|
Additional
|
|
|
Accumulated |
|
Total
|
|
Common Stock |
|
|
Additional
|
|
|
Accumulated |
|
Total
|
||||||||||||||||||||
|
|
Shares |
|
|
Amount |
|
|
Capital |
|
|
Deficit |
|
Equity |
|
Shares |
|
|
Amount |
|
|
Capital |
|
|
Deficit |
|
Equity |
||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||
Balances at beginning of period |
|
|
111,856,473 |
|
|
$ |
1,119,000 |
|
|
$ |
132,612,000 |
|
|
$ |
(136,595,000 |
) |
|
$ |
(2,864,000 |
) |
|
|
111,856,473 |
|
|
$ |
1,119,000 |
|
|
$ |
132,398,000 |
|
|
$ |
(133,245,000 |
) |
|
$ |
272,000 |
|
Share-based compensation expense - stock options |
|
|
— |
|
|
|
— |
|
|
|
84,000 |
|
|
|
— |
|
|
|
84,000 |
|
|
|
— |
|
|
|
— |
|
|
|
144,000 |
|
|
|
— |
|
|
|
144,000 |
|
Share-based compensation expense - restricted stock units |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net loss |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(1,487,000 |
) |
|
|
(1,487,000 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(1,737,000 |
) |
|
|
(1,737,000 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Balances at end of period (Unaudited) |
|
|
111,856,473 |
|
|
$ |
1,119,000 |
|
|
$ |
132,696,000 |
|
|
$ |
(138,082,000 |
) |
|
$ |
(4,267,000 |
) |
|
|
111,856,473 |
|
|
$ |
1,119,000 |
|
|
$ |
132,542,000 |
|
|
$ |
(134,982,000 |
) |
|
$ |
(1,321,000 |
) |
|
|
Three Months Ended January 31, 2025 |
|
Three Months Ended January 31, 2024 |
||||||||||||||||||||||||||||||||||||
|
|
Common Stock |
|
|
Additional
|
|
|
Accumulated |
|
Total
|
|
Common Stock |
|
|
Additional
|
|
|
Accumulated |
|
Total
|
||||||||||||||||||||
|
|
Shares |
|
|
Amount |
|
|
Capital |
|
|
Deficit |
|
Equity |
|
Shares |
|
|
Amount |
|
|
Capital |
|
|
Deficit |
|
Equity |
||||||||||||||
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||||||||||||
Balances at beginning of period (Unaudited) |
|
|
111,856,473 |
|
|
$ |
1,119,000 |
|
|
$ |
132,669,000 |
|
|
$ |
(137,284,000 |
) |
|
$ |
(3,496,000 |
) |
|
|
111,856,473 |
|
|
$ |
1,119,000 |
|
|
$ |
132,478,000 |
|
|
$ |
(133,980,000 |
) |
|
$ |
(383,000 |
) |
Share-based compensation expense - stock options |
|
|
— |
|
|
|
— |
|
|
|
27,000 |
|
|
|
— |
|
|
|
27,000 |
|
|
|
— |
|
|
|
— |
|
|
|
64,000 |
|
|
|
— |
|
|
|
64,000 |
|
Share-based compensation expense - restricted stock units |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Net loss |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(798,000 |
) |
|
|
(798,000 |
) |
|
|
— |
|
|
|
— |
|
|
|
— |
|
|
|
(1,002,000 |
) |
|
|
(1,002,000 |
) |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
||||
Balances at end of period (Unaudited) |
|
|
111,856,473 |
|
|
$ |
1,119,000 |
|
|
$ |
132,696,000 |
|
|
$ |
(138,082,000 |
) |
|
$ |
(4,267,000 |
) |
|
|
111,856,473 |
|
|
$ |
1,119,000 |
|
|
$ |
132,542,000 |
|
|
$ |
(134,982,000 |
) |
|
$ |
(1,321,000 |
) |
PURE Bioscience, Inc. Condensed Consolidated Statements of Cash Flows (Unaudited) |
||||||||
|
|
Six Months Ended |
||||||
|
|
January 31, |
||||||
|
|
2025 |
|
|
2024 |
|
||
Operating activities |
|
|
|
|
|
|
||
Net loss |
|
$ |
(1,487,000 |
) |
|
$ |
(1,737,000 |
) |
Adjustments to reconcile net loss to net cash used in operating activities: |
|
|
|
|
|
|
||
Share-based compensation |
|
|
84,000 |
|
|
|
144,000 |
|
Depreciation and amortization |
|
|
1,000 |
|
|
|
74,000 |
|
Changes in operating assets and liabilities: |
|
|
|
|
|
|
||
Accounts receivable |
|
|
118,000 |
|
|
|
114,000 |
|
Inventories |
|
|
(19,000 |
) |
|
|
14,000 |
|
Prepaid expenses |
|
|
(3,000 |
) |
|
|
(1,000 |
) |
Interest on note payable to related parties |
|
|
126,000 |
|
|
|
56,000 |
|
Accounts payable and accrued liabilities |
|
|
133,000 |
|
|
|
13,000 |
|
Net cash used in operating activities |
|
|
(1,047,000 |
) |
|
|
(1,323,000 |
) |
Financing activities |
|
|
|
|
|
|
||
Net proceeds from note payable to related parties |
|
|
900,000 |
|
|
|
785,000 |
|
Net cash provided by financing activities |
|
|
900,000 |
|
|
|
785,000 |
|
Net decrease in cash, cash equivalents, and restricted cash |
|
|
(147,000 |
) |
|
|
(538,000 |
) |
Cash, cash equivalents, and restricted cash at beginning of period |
|
|
424,000 |
|
|
|
1,170,000 |
|
Cash, cash equivalents, and restricted cash at end of period |
|
$ |
277,000 |
|
|
$ |
632,000 |
|
|
|
|
|
|
|
|
||
Reconciliation of cash, cash equivalents, and restricted cash to the condensed consolidated balance sheets |
|
|
|
|
|
|
||
Cash and cash equivalents |
|
$ |
202,000 |
|
|
$ |
557,000 |
|
Restricted cash |
|
$ |
75,000 |
|
|
$ |
75,000 |
|
Total cash, cash equivalents and restricted cash |
|
$ |
277,000 |
|
|
$ |
632,000 |
|
|
|
|
|
|
|
|
||
Supplemental disclosure of cash flow information |
|
|
|
|
|
|
||
Cash paid for taxes |
|
$ |
— |
|
|
|
— |
|
View source version on businesswire.com: https://www.businesswire.com/news/home/20250317255290/en/
Mark Elliott, VP Finance
PURE Bioscience, Inc.
619-596-8600 ext.: 116
Source: PURE Bioscience, Inc.